RecruitingPhase 1NCT06943677
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors
Studying Catastrophic antiphospholipid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Intervention
- TQB3019 capsules(drug)
- Enrollment
- 80 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (15)
- Cancer Institute & Hospital.Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
- Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
- The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
- Jiangsu Province Hospital, Nanjing, Jiangsu, China
- The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
- The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
- Heze Municipal Hospital, Heze, Shandong, China
- The Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
- The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
- Tongji Hospital of Tongji University, Shanghai, Shanghai Municipality, China
- The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
- Mianyang Central Hospital, Mianyang, Sichuan, China
- Affiliated Hospital of North sichuan Medical college, Nanchong, Sichuan, China
- TianJin Medical University Cancer Institute&Hospital, Tianjin, Tianjin Municipality, China
- Institute of Hematology ＆Blood Diseases Hospital,Chinese Academy of Medical Sciences ＆Peking Union Medical College, Tianjin, Tianjin Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06943677 on ClinicalTrials.govOther trials for Catastrophic antiphospholipid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07458984FMT Capsules for rCDIHelsinki University Central Hospital
- RECRUITINGPHASE1NCT07297199A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55Biogen
- RECRUITINGPHASE3NCT07165951Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- RECRUITINGNANCT07561333Comparing ACB+IPACK and ACB+BiFeS Block Combinations for Analgesia in Total Knee ArthroplastyHitit University
- RECRUITINGPHASE2, PHASE3NCT06841679Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction AdenocarcinomaBeijing Biostar Pharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT07044271A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy ParticipantsEli Lilly and Company
- RECRUITINGPHASE2NCT06822946Zhibitai Capsules for the Treatment of Primary HyperlipidemiaChengdu Diao Jiuhong Pharmaceutical Factory
- RECRUITINGPHASE1NCT06796699A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid TumorsSuzhou Genhouse Bio Co., Ltd.